Application of antiangiogenesis therapy in the radiotherapy of esophageal cancer

doi:10.3760/cma.j.issn.1673-422X.2017.06.017

Abstract

Abstract: Radiotherapy is the principle method of nonsurgical treatment for esophageal cancer. The 5year survival rate ranges from 20% to 40%. In recent years, the studies have found that antiangiogenesis therapy can not only directly inhibit tumor nutritional intake, but also turn around tumor hypoxia by normalizing tumor vessels so as to enhance the radiosensitivity of tumor cells, which is expected to become an effective way to improve the curative effect of esophageal cancer radiotherapy.

Key words: Esophageal neoplasms, Radiotherapy, Angiogenesis inhibitors

Feng Yue, Yu Jingping, Wang Jianlin. Application of antiangiogenesis therapy in the radiotherapy of esophageal cancer[J]. Journal of International Oncology, 2017, 44(6): 468-.

References

［1］ Chen M, Cai E, Huang J, et al. Prognostic value of vascular endothelia growth factor expression in patients with esophageal cancer: a systematic review and metaanalysis［J］. Cancer Epidemiol Biomarkers Prev, 2012, 21(7): 1126-1134. DOI: 10.1158/10559965.EPI120020. ［2］ Yu JP, Lu WB, Wang JL, et al. Pathologic response during chemoradiotherapy and variation of serum VEGF levels could predict effects of chemoradiotherapy in patients with esophageal cancer［J］. Asian Pac J Cancer Prev, 2015, 16(3): 1111-1116. ［3］ Willett CG, Boucher Y, Duda DG, et al. Surrogate markers for antiangiogenic therapy and doselimiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase Ⅰ trial in rectal cancer patients［J］. J Clin Oncol, 2005, 23(31): 8136-8139. ［4］ Ku GY, Bains MS, Park DJ, et al. Phase Ⅱ study of bevacizumab and preoperative chemoradiation for esophageal adenocarcinoma［J］. J Gastrointest Oncol, 2016, 7(6): 828-837. DOI: 10.21037/jgo.2016.08.09. ［5］ Fuchs CS, Tomasek J, Yong CJ, et al. Ramucirumab monotherapy for previously treated advanced gastric or gastrooesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebocontrolled, phase 3 trial［J］. Lancet, 2014, 383(9911): 31-39. DOI: 10.1016/s01406736(13)617195．［6］ McLarnon A. 2014 Gastrointestinal Cancers Symposium［J］. Lancet Oncol, 2014, 15(3): 262. DOI: 10.1016/s14702045(13)703401. ［7］孙志强, 于静萍, 张志明, 等. 重组人血管内皮抑素对食管癌细胞的放射增敏作用及其机制［J］. 中华放射医学与防护杂志, 2013, 33(4): 346-350. DOI: 10.3760/cma.j.issn.02545098.2013.04.003. ［8］ Jiang Y, Xu W. Effect of endostar combined with radiation therapy for esophageal squamous cell carcinoma on blood perfusion and early efficacy［J］. Int J Radiat Oncol Biol Phys, 2016, 96(2S): E217. DOI: 10.1016/j.ijrobp.2016.06.1135. ［9］ Zhong Z, Gu X, Zhang Z, et al. Recombinant human endostatin combined with definitive chemoradiotherapy as primary treatment for patients with unresectable but without systemic metastatic squamous cell carcinoma of the oesophagus［J］. Br J Radiol, 2012, 85(1019): e1104-e1109. DOI: 10.1259/bjr/15321801. ［10］ Ding YQ, Zhu HC, Chen XC, et al. Sunitinib modulates the radiosensitivity of esophageal squamous cell carcinoma cells in vitro［J］. Dis Esophagus, 2016, 29(8): 1144-1151. DOI: 10.1111/dote.12440. ［11］ Kleibeuker EA, Ten Hooven MA, Castricum KC, et al. Optimal treatment scheduling of ionizing radiation and sunitinib improves the antitumor activity and allows dose reduction［J］. Cancer Med, 2015, 4(7): 1003-1015. DOI: 10.1002/cam4.441. ［12］ Horgan AM, Darling G, Wong R, et al. Adjuvant sunitinib following chemoradiotherapy and surgery for locally advanced esophageal cancer: a phase Ⅱ trial［J］. Dis Esophagus, 2016, 29(8): 1152-1158. DOI: 10.1111/dote.12444. ［13］ Ku GY, Janjigian YY, Shah MA, et al. Phase Ⅱ trial of sorafenib in esophageal (E) and gastroesophageal junction (GEJ) cancer: response and prolonged stable disease observed in adenocarcinoma［J］. J Clin Oncol, 2013, 33(4part2): 848-866. ［14］ Janjigian YY, Vakiani E, Ku GY, et al. Phase Ⅱ trial of Sorafenib in patients with chemotherapy refractory metastatic esophageal and gastroesophageal (GE) junction cancer［J］. PLoS One, 2015, 10(8): e0134731. DOI: 10.1371/journal.pone.0134731. ［15］ Zhang H. Apatinib for molecular targeted therapy in tumor［J］. Drug Des Devel Ther, 2015, 9: 6075-6081. DOI: 10.2147/DDDT.S97235. ［16］ Ding J, Chen X, Dai X, et al. Simultaneous determination of apatinib and its four major metabolites in human plasma using liquid chromatographytandem mass spectrometry and its application to a pharmacokinetic study［J］. J Chromatogr B Analyt Technol Biomed Life Sci, 2012, 895896: 108-115. DOI: 10.1016/j.jchromb.2012.03.027. ［17］ Li J, Qin S, Xu J, et al. Apatinib for chemotherapyrefractory advanced metastatic gastric cancer: results from a randomized, placebocontrolled, parallelarm, phase Ⅱ trial［J］. J Clin Oncol, 2013, 31(26): 3219-3225. DOI: 10.1200/jco.2013.48.8585. ［18］ Li J, Qin S, Xu J, et al. O0029 phase Ⅲ study of apatinib in advanecd gastric cancer: a randomized, doubleblind, placebocontrolled trial［J］. J Clin Oncol, 2014, 25(suppl 2): ii117. DOI: 10.1093/annonc/mdu193.29. ［19］ Pavlakis N, Sjoquist KM, Tsobanis E, et al. LBA06 INTEGRATE: a randomized phase Ⅱ doubleblind placebocontrolled study of regorafenib (REG) in refractory advanced oesophagogastric cancer (AOGC)—a study by the Australasian Gastrointestinal Trials Group (AGITG): final overall and subgroup results［J］. Ann Oncol, 2015, 26(suppl 4): iv119. DOI: 10.1093/annonc/mdv262.06. ［20］ Grothey A, Van Cutsem E, Sobrero A, et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebocontrolled, phase 3 trial［J］. Lancet, 2013, 381(9863): 303-312. DOI: 10.1016/s01406736(12)61900x. ［21］ Demetri GD, Reichardt P, Kang YK, et al. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebocontrolled, phase 3 trial［J］. Lancet, 2013, 381(9863): 295-302. DOI: 10.1016/s01406736(12)618571. ［22］ Yu J, Liu F, Sun M, et al. Enhancement of radiosensitivity and the potential mechanism on human esophageal carcinomacells by tetrandrine［J］. Cancer Biother Radiopharm, 2011, 26(4): 437-442. DOI: 10.1089/cbr.2011.0964. ［23］ Yu JP, Sun SP, Sun ZQ, et al. Clinical trial of thalidomide combined with radiotherapy in patients with esophageal cancer［J］. World J Gastroenterol, 2014, 20(17): 5098-5103. DOI: 10.3748/wjg.v20.i17.5098.

[1]	Qian Xiaotao, Shi Ziyi, Hu Ge, Wu Xiaowei. Efficacy of consolidation chemotherapy after radical radiotherapy and chemotherapy for stage Ⅲ-ⅣA esophageal squamous cell carcinoma： a real-world clinical study [J]. Journal of International Oncology, 2024, 51(6): 326-331.
[2]	Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun. Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer [J]. Journal of International Oncology, 2024, 51(6): 332-337.
[3]	Gao Fan, Wang Ping, Du Chao, Chu Yanliu. Research progress on intestinal flora and non-surgical treatment of the colorectal cancer [J]. Journal of International Oncology, 2024, 51(6): 376-381.
[4]	Liu Jing, Liu Qin, Huang Mei. Prognostic model construction of lung infection in patients with chemoradiotherapy for esophageal cancer based on SMOTE algorithm [J]. Journal of International Oncology, 2024, 51(5): 267-273.
[5]	Wan Fang, Yang Gang, Li Rui, Wan Qijing. Expression levels and clinical significance of serum miR-497 and miR-383 in patients with esophageal cancer [J]. Journal of International Oncology, 2024, 51(4): 204-209.
[6]	Qian Xiaotao, Shi Ziyi, Hu Ge. A real-world clinical study of immunocheckpoint inhibitor maintenance therapy after radical radiotherapy and chemotherapy in stage Ⅲ-ⅣA esophageal squamous cell carcinoma [J]. Journal of International Oncology, 2024, 51(3): 151-156.
[7]	Li Shuyue, Ma Chenying, Zhou Juying, Xu Xiaoting, Qin Songbing. Progress of radiotherapy in oligometastatic non-small cell lung cancer [J]. Journal of International Oncology, 2024, 51(3): 170-174.
[8]	Gao Xinyu, Li Zhenjiang, Sun Hongfu, Han Dan, Zhao Qian, Liu Chengxin, Huang Wei. Clinical application of MR-guided radiotherapy based on MR-linac in esophageal cancer patients [J]. Journal of International Oncology, 2024, 51(1): 37-42.
[9]	Cui Tenglu, Lyu lu, Sun Pengfei. Application of radiotherapy combined with immunotherapy in the treatment of head and neck squamous cell carcinoma [J]. Journal of International Oncology, 2023, 50(9): 548-552.
[10]	Shandong Medical Association Multidisciplinary Joint Committee on Lung Cancer. Shandong Provincial Medical Association multidisciplinary standardized diagnosis and treatment guidelines for esophageal carcinoma （2023 Edition） [J]. Journal of International Oncology, 2023, 50(7): 385-397.
[11]	Li Qingshan, Xie Xin, Zhang Nan, Liu Shuai. Research progress on the application of combining radiotherapy and systemic therapy in breast cancer [J]. Journal of International Oncology, 2023, 50(6): 362-367.
[12]	Lyu Lu, Sun Pengfei. Gut flora and cervical cancer [J]. Journal of International Oncology, 2023, 50(6): 373-376.
[13]	Radiation Oncology Treatment Physician Branch, Chinese Medical Doctor Association, Radiation Oncology Therapy Branch, Chinese Medical Association, Chinese Association of Radiation Therapy, China Anti-Cancer Association. Chinese experts' consensus on the application of pegylated recombinant human granulocyte colony-stimulating factor during concurrent chemoradiotherapy （2023 version） [J]. Journal of International Oncology, 2023, 50(4): 193-201.
[14]	Xu Meng, Jiang Wei, Zhu Haitao, Cao Xiongfeng. Research progress of cancer-associated fibroblasts in tumor radiotherapy resistance [J]. Journal of International Oncology, 2023, 50(4): 227-230.
[15]	Shi Xaioqi, Wang Hongyan. Research progress on the interaction between gut microbiota and radiation enteritis [J]. Journal of International Oncology, 2023, 50(4): 244-247.